Biomage is Acquired by Parse Biosciences

 

Bringing powerful wet-lab and data analytics technologies to researchers

We are excited to announce that Biomage has been acquired by Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions!

As a result of the acquisition, Parse Biosciences customers will soon have access to a rich suite of user-friendly and accessible single cell data analysis tools. By pairing Biomage’s powerful data analysis tools with Parse’s Evercode combinatorial barcoding technology, researchers will gain deeper biological insights with dramatically reduced analysis time.

The Biomage-hosted instance of Cellenics will continue to be available

Biomage currently hosts and supports the largest community instance of Cellenics®, a cloud-based single cell RNA sequencing data analysis platform that brings powerful analysis tools to researchers without the need for bioinformatics expertise. Following the acquisition, the Cellenics® platform previously hosted by Biomage continues to be available for use by researchers - all user scientific data is preserved and access by current and new Cellenics® community members will continue.

Looking towards an exciting future

“The platform has quickly become a trusted resource for single cell researchers around the world,” said Parse Biosciences co-founder and CTO Charles Roco. “Integrating the software into Parse’s portfolio of offerings will give our customers access to rich, dynamic exploration of single cell data in a shorter amount of time than anything currently available.”

“The combination of Parse’s scalability – which allows for exponentially larger experiments than other single cell technologies – and Biomage-developed technology to speed up analysis is an unbeatable combination that is going to have wide-ranging, positive implications for the single cell community,” noted Biomage co-founder and CEO Adam Kurkiewicz.

As all current Biomage staff members are being integrated into the existing Parse team, we’re delighted to continue supporting the research community by bringing state-of-the-art data analysis tools to the spotlight.

 
Next
Next

Scientist Kevin Matthew Byrd, DDS, PhD, founder of the Human Cell Atlas Oral & Craniofacial Bio-network, publishes pre-print article using CellenicsⓇ